MANE - CIK 0001827635
The table below shows Veradermics, Inc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 |
|---|---|---|
| Operating cash flow | -$21.17M | -$13.32M |
| Capital expenditure | $0.00 | $19.00K |
| Investing cash flow | -$101.30M | -$15.75M |
| Dividends paid | - | - |
| Stock buybacks | - | - |
| Financing cash flow | $269.11M | $8.42M |
Veradermics, Inc reported operating cash flow of -$71.60M for fiscal year 2025. That is down 202.3% from -$23.69M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.